| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1359/JBMR.050814 |
| P698 | PubMed publication ID | 16294263 |
| P2093 | author name string | Piet Geusens | |
| Nelson B Watts | |||
| Dieter Felsenberg | |||
| Ian P Barton | |||
| P2860 | cites work | Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? | Q36017145 |
| P433 | issue | 12 | |
| P921 | main subject | bone fracture | Q68833 |
| P304 | page(s) | 2097-2104 | |
| P577 | publication date | 2005-08-08 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. | |
| P478 | volume | 20 |
| Q46239085 | Analysis of factors affecting increase in bone mineral density at lumbar spine by bisphosphonate treatment in postmenopausal osteoporosis |
| Q35017714 | Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products |
| Q37646960 | Bone loss or lost bone: rationale and recommendations for the diagnosis and treatment of early postmenopausal bone loss |
| Q33931909 | Choosing wisely: the American College of Rheumatology's Top 5 list of things physicians and patients should question. |
| Q37731292 | Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy |
| Q37477158 | Clodronic acid formulations available in Europe and their use in osteoporosis: a review |
| Q38367370 | Co-administration of antiresorptive and anabolic agents: a missed opportunity |
| Q37107665 | DXA scanning in clinical practice. |
| Q30476071 | Dynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosis |
| Q35230210 | Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study |
| Q51482952 | Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures. |
| Q24612411 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
| Q37037296 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
| Q57465255 | European guidance for the diagnosis and management of osteoporosis in postmenopausal women |
| Q53221347 | Evolve osteoporosis and other guidelines avoiding cognitive bias. |
| Q47189134 | Factors Affecting Bone Mineral Density Measurement after Fracture in South Korea |
| Q35536507 | Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study |
| Q44820755 | Fracture risk remains reduced one year after discontinuation of risedronate |
| Q57711404 | Goal-directed therapy in osteoporosis |
| Q44874767 | Goal-directed treatment of osteoporosis |
| Q36809342 | High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group. |
| Q37135281 | Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. |
| Q30831057 | Magnetic resonance imaging assessed cortical porosity is highly correlated with μCT porosity. |
| Q38145005 | Measuring bone quality. |
| Q34009569 | Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. |
| Q35653722 | Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. |
| Q79825633 | Monitoring osteoporosis therapies |
| Q34626494 | Off-axis loads cause failure of the distal radius at lower magnitudes than axial loads: a finite element analysis. |
| Q35144237 | Osteopenia: a diagnostic and therapeutic challenge |
| Q36019924 | Parametric response mapping of CT images provides early detection of local bone loss in a rat model of osteoporosis. |
| Q51369601 | Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. |
| Q33956586 | Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA. |
| Q57168211 | Prophylactic Bisphosphonate Treatment Prevents Bone Fractures After Liver Transplantation |
| Q36153174 | Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. |
| Q35774970 | Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture |
| Q35678676 | Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis |
| Q37145844 | Technology insight: noninvasive assessment of bone strength in osteoporosis |
| Q38029394 | The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction |
| Q83033686 | To stop or not to stop, that is the question |
| Q35961807 | Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice |
| Q36543142 | Treating osteoporosis: economic aspects of bisphosphonate therapy |
| Q57417008 | Treatment failure in osteoporosis |
| Q37298025 | Treatment responses with once-weekly teriparatide therapy for osteoporosis |
| Q97686573 | Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials |
| Q36045845 | Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis |
| Q83518547 | [Current diagnosis and therapy of osteoporosis on the basis of "European guidance 2008"] |
| Q79210170 | [Follow-up of osteoporosis treatment] |
Search more.